S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:NMTC

NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis

$1.18
+0.03 (+2.61%)
(As of 04/17/2024 ET)
Today's Range
$1.14
$1.18
50-Day Range
$1.03
$1.45
52-Week Range
$0.85
$2.00
Volume
46,339 shs
Average Volume
183,937 shs
Market Capitalization
$30.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.20

NeuroOne Medical Technologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.4% Upside
$2.20 Price Target
Short Interest
Healthy
1.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

Medical Sector

725th out of 913 stocks

Surgical & Medical Instruments Industry

74th out of 89 stocks

NMTC stock logo

About NeuroOne Medical Technologies Stock (NASDAQ:NMTC)

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

NMTC Stock Price History

NMTC Stock News Headlines

Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Neuroone Medical Technologies Corp (NMTC)
NMTC Jul 2024 2.500 call
NeuroOne Medical Technologies Corporation Registered Shs
NeuroOne Medical Technologies earnings: here's what Wall Street expects
NeuroOne Medical Technologies Corp.
See More Headlines
Receive NMTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroOne Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NMTC
Fax
N/A
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.20
High Stock Price Target
$2.20
Low Stock Price Target
$2.20
Potential Upside/Downside
+86.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-11,860,000.00
Net Margins
-478.41%
Pretax Margin
-478.37%

Debt

Sales & Book Value

Annual Sales
$1.95 million
Book Value
$0.26 per share

Miscellaneous

Free Float
23,986,000
Market Cap
$30.60 million
Optionable
Optionable
Beta
0.81
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

NMTC Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroOne Medical Technologies stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeuroOne Medical Technologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NMTC shares.
View NMTC analyst ratings
or view top-rated stocks.

What is NeuroOne Medical Technologies' stock price target for 2024?

1 brokers have issued 12 month target prices for NeuroOne Medical Technologies' shares. Their NMTC share price targets range from $2.20 to $2.20. On average, they anticipate the company's share price to reach $2.20 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price.
View analysts price targets for NMTC
or view top-rated stocks among Wall Street analysts.

How have NMTC shares performed in 2024?

NeuroOne Medical Technologies' stock was trading at $1.58 at the beginning of 2024. Since then, NMTC shares have decreased by 25.3% and is now trading at $1.18.
View the best growth stocks for 2024 here
.

Are investors shorting NeuroOne Medical Technologies?

NeuroOne Medical Technologies saw a increase in short interest in March. As of March 31st, there was short interest totaling 365,300 shares, an increase of 133.0% from the March 15th total of 156,800 shares. Based on an average daily volume of 195,400 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.7% of the shares of the stock are sold short.
View NeuroOne Medical Technologies' Short Interest
.

When is NeuroOne Medical Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NMTC earnings forecast
.

How were NeuroOne Medical Technologies' earnings last quarter?

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) released its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.14) EPS for the quarter. The company had revenue of $0.98 million for the quarter. NeuroOne Medical Technologies had a negative net margin of 478.41% and a negative trailing twelve-month return on equity of 267.82%.

How do I buy shares of NeuroOne Medical Technologies?

Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMTC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners